Investment Research Analysts Opinion: Forterra, Inc. (FRTA), Arrowhead Pharmaceuticals, Inc. (ARWR)

The Lower end of the earnings estimate is $-0.24, while the higher end of the earnings estimate is $-0.07.

Many analysts are providing their Estimated Earnings analysis for Arrowhead Pharmaceuticals, Inc. and for the current quarter 4 analysts have projected that the stock could give an Average Earnings estimate of $-0.1/share.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 3rd. They expect $-0.13 EPS, up 58.06% or $0.18 from last year's $-0.31 per share. The difference between the expected and actual EPS was $0.07/share, which represents an Earnings surprise of 50%. The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 3.00, which implies that analysts are generally neutral in their outlook for ARWR over the next year.

Arrowhead Pharmaceuticals, (NASDAQ:ARWR) gapped up before the market opened on early Tue. the share had previously closed at $3.34, but started trading at $3.43. The company earned $4.37 million during the quarter, compared to analyst estimates of $13.24 million. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. The correct version of this piece of content can be accessed at

ARWR is now overvalued by 135.33% relative to the average 1-year price target of $1.50 taken from a group of Wall Street Analysts. Lastly, Jefferies reissued a "hold" recommendation and fixed a $2.00 price objective on the stock of Arrowhead Pharmaceuticals in a note on Fri, Aug 4th. The stock has "Hold" rating by Cantor Fitzgerald on Wednesday, November 30. Jefferies Group now has a "Hold" rating and a $2.00 target price on the stock.

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) traded up 0.29% during mid-day trading on Tuesday, reaching $3.44. Institutional investors own 20.63% of the company's stock. Analysts have placed a $1.5 price target on Arrowhead Pharmaceuticals, Inc., suggesting a -56.27% decline from recent close. Trading volume was up 200.48% over the stocks average daily volume.

The volume of the particular stock is the shares bought and sold in a single trading day. Wells Fargo & Company MN lifted its stake in shares of Arrowhead Pharmaceuticals by 144.8% in the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company's stock valued at $123,000 after purchasing an additional 53,500 shares in the last quarter. Bank of Montreal Can raised its position in shares of Arrowhead Pharmaceuticals by 4,355.8% in the third quarter. Moors & Cabot Inc. raised its position in shares of Arrowhead Pharmaceuticals by 11.0% in the third quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company's stock valued at $186,000 after purchasing an additional 74,776 shares in the last quarter. Virtu KCG Holdings LLC lifted its position in shares of Arrowhead Pharmaceuticals by 115.6% during the 2nd quarter. Virtu KCG Holdings has an ownership of 99,267 stocks of the biotechnology firms shares valued $161,000 following acquiring an extra 53,215 stocks in the previous period.

This company has been competing with others in the Healthcare space and offers its own combination of interesting factors Arrowhead Pharmaceuticals, Inc. "(ARWR) Given Average Recommendation of "Hold" by Analysts" was originally published by StockNewsTimes and is the sole property of of StockNewsTimes.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company.

Like this


19 September 2017
WWE Starrcade Live Event Announced for November
Also on the bill are The Hardy Boyz , who are from the RAW brand, but are making a special appearance in their home state. This will be SmackDown Live-exclusive, and a WWE Network Special Event similar to the first Roadblock in March of 2016.

19 September 2017
Mitchell Robinson to skip college, begin training for NBA Draft
Robinson, who had re-enrolled at WKU in late August, plans to bypass college and train to play professional basketball in the NBA. It had been speculated he would not be able to transfer to another Division I school and play in games during the 2017-18 season.

18 September 2017
USA stages bombing drills with South Korea
China and Russian Federation have begun a naval military maneuver near North Korea , reports Reuters . Coal briquettes made up the largest percentage of North Korea's exports in 2015.

18 September 2017
Check out this new interactive trailer for Middle-Earth: Shadow of War
Players will continue the adventures of Talion as he tries to thwart the increasing threat of Sauron and his Nazgul forces. That's a decent duo of talented folks involved in the making of this interactive live-action film.

18 September 2017
Kate McKinnon wins best comedy supporting actress at 2017 Emmys
The 33-year-old actress won for her role on Saturday Night Live , where she often impersonates the former presidential candidate. Clinton included her reaction to McKinnon's portrayal in the chapter titled "Grit and Gratitude".

18 September 2017
Bobo trial continues after brief weekend session
The judge started the court's one-hour lunch recess early because the heat came on in the courtroom. The jury heard playback of a 911 call between a dispatcher and Dick Adams, Zach Adams' grandfather.

18 September 2017
Fosun to acquire Gland Pharma, with smaller stake
Raju, will remain on the Gland board and the current management team will continue to run the company. Fosun Pharma shares yesterday jumped as much as 4.3 percent in Shanghai.

18 September 2017
Source Says Nicki Minaj And Nas Have Been Dating Since May
According to Nasty Nas , the '80s-themed shoot was part of an upcoming video, which will be released soon. Recently, a report surfaced about just how much Nicki cares about her bae.

18 September 2017
Burning Stock on the move: Cisco Systems, Inc. (CSCO)
The highest price CSCO stock touched in the last 12 month was $34.6 and the lowest price it hit in the same period was $29.12. Also, CEO Charles Robbins sold 121,390 shares of the company's stock in a transaction dated Wednesday, September 13th.

18 September 2017
Paychex, Inc. (PAYX) Analysts See $0.60 EPS; Xerium Technologies Has 0.81 Sentiment
Triangle Securities Wealth Management bought 4,330 shares as the company's stock declined 1.76% while stock markets rallied. Tributary Capital Management Limited Liability Company owns 0.34% invested in Paychex, Inc. (NASDAQ:PAYX) for 4,690 shares.